Bard gains "promising" balloon tech with Lutonix buy
This article was originally published in Clinica
Executive Summary
CR Bard has acquired drug-eluting balloon developer Lutonix in a deal worth up to $325m, giving it access to the only DEB in US trials for peripheral arterial disease. Bard has paid $225m upfront, and will shell out a further $100m if Lutonix's device gains US FDA premarket approval (PMA). PMA submission is expected in 2014.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.